{"id":"W3047400464","doi":"10.1016/j.annonc.2020.07.001","title":"The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Arnold Ventures; Roche; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Ipilimumab; Oncology; Family medicine; Internal medicine; Lung cancer; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386605,0.000353161,0.001432811,0.0001632685,0.0001347727,0.00001071493,0.0005407305,0.0004525637,0.0001299143],"category_scores_gemma":[0.002678256,0.0002045021,0.0003417383,0.0002313556,0.0008168601,0.0000465985,0.0002969157,0.00097942,0.00004660973],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001357715,"about_ca_system_score_gemma":0.00125558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004664551,"about_ca_topic_score_gemma":0.00004483418,"domain_scores_codex":[0.9968442,0.0001621434,0.0007262132,0.0005306717,0.001052501,0.0006843273],"domain_scores_gemma":[0.9933837,0.002688852,0.0006189229,0.0006603695,0.002516738,0.0001313967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01152317,0.0002696763,0.0004555903,0.0009298414,0.001127974,0.00017524,0.000246516,7.60335e-7,0.000009645928,0.00001259323,0.9648827,0.02036633],"study_design_scores_gemma":[0.006013174,0.02134203,0.0009016781,0.0003672861,0.0002648929,0.000009785106,0.00004885038,0.00001477725,0.00006669456,0.0002808584,0.9705162,0.0001737597],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.007659433,0.00121505,0.00004223272,0.9775727,0.0005272388,0.003271024,0.0004804257,0.00002903545,0.009202817],"genre_scores_gemma":[0.02484317,0.004616013,0.00482762,0.9345333,0.007604616,0.002058142,0.001137938,0.000354603,0.02002459],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04303944,"threshold_uncertainty_score":0.8339356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07303249655138225,"score_gpt":0.4114210955109136,"score_spread":0.3383885989595313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}